Levomethadyl

Contraindicated

Levomethadyl Amitriptyline Elavil Explained An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Levomethadyl Chloroquine Aralen® An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Levomethadyl Disopyramide Norpace An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Levomethadyl Dofetilide Tikosyn An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Levomethadyl Dolasetron Anzemet An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Levomethadyl Dolasetron Injection Anzemet An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Levomethadyl Flecainide Tambocor® An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Levomethadyl Flucytosine An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Levomethadyl Foscarnet Injection Foscavir An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Levomethadyl Linezolid Injection Zyvox Increased levels of levomethadyl or its active metabolites Details Levomethadyl Mefloquine Lariam® An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Levomethadyl Mexiletine Mexitil® An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Levomethadyl Octreotide Bynfezia An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Levomethadyl Octreotide Injection Bynfezia An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details

Major

Levomethadyl Acetazolamide Diamox® Sequels® Increased risk of QT prolongation Details Levomethadyl Arsenic Trioxide Trisenox An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Levomethadyl Arsenic Trioxide Injection Trisenox An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Levomethadyl Asciminib Scemblix Increased CYP3A4 exposure and an increased risk of CYP3A4-related adverse reactions Details Levomethadyl Castor Oil Increased risk of QT prolongation Details Levomethadyl Enasidenib Idhifa Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Levomethadyl Encorafenib Braftovi Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Levomethadyl Furosemide Injection Disal Increased risk of QT prolongation Details Levomethadyl Gemifloxacin Factive An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Levomethadyl Ketoconazole Topical Extina® Foam Increased levomethadyl exposure Details Levomethadyl Lactulose Cholac® Increased risk of QT prolongation Details Levomethadyl Lanreotide Injection Somatuline Altered exposure to CYP3A4 substrate Details Levomethadyl Lefamulin Xenleta Increased sensitive CYP3A4 substrate exposure and an increased risk of sensitive CYP3A4 substrate-related toxicities associated wi... Details Levomethadyl Lenacapavir Injection Sunlenca Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-mediated adverse reactions Details Levomethadyl Lenacapavir Oral Sunlenca Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-mediated adverse reactions Details Levomethadyl Letermovir Injection Prevymis Increased CYP3A substrate exposure Details Levomethadyl Mitapivat Aqvesme Reduced CYP3A substrate exposure Details